Nasdaq · CIK 0000875045 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
BIOGEN INC.
BIIB chart by TradingView
PRICE HISTORY
LIVE · NASDAQBIIB chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $9.9B
- EBITDA
- —
- FREE CASH FLOW
- $2.1B
- EPS
- $8.79
- GROSS MARGIN
- 75.69%
- ROIC
- —
Q1 FY26ENDED MAR 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
19.8x
+43%7.3x32.3x
⤢
P / SALES (TTM)
2.7x
-42%1.8x6.0x
⤢
P / BOOK
1.5x
-69%1.0x5.7x
⤢
EV / EBITDA (TTM)
—
-21%6.4x12.2x
⤢
EV / REVENUE (TTM)
—
-23%3.2x6.4x
⤢
FCF YIELD (TTM)
8.91%
+2.4pp2.76%15.37%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$2.5B
-14%⤢
EBITDA (DERIVED)
—
-51%⤢
NET INCOME
$0.3B
-70%⤢
EPS (DILUTED)
$2.15
-55%⤢
REVENUE GROWTH YOY
1.93%
-9.8pp-24.63%15.15%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
23.98%
-5.8pp-15.88%50.39%
⤢
RETURN ON CAPITAL
—
+12.9pp14.96%35.94%
⤢
RETURN ON EQUITY (TTM)
7.36%
-26.1pp7.08%52.41%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN73.32%
OPERATING MARGIN—
NET MARGIN12.89%
FCF MARGIN23.98%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.6B
-31%⤢
STOCK-BASED COMP
$0.1B
+116%⤢
CAPITAL EXPENDITURE
$0.1B
-63%⤢
SHARES OUTSTANDING
0.15B
-32%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
—
+114%⤢
TOTAL DEBT
$6.3B
-4%⤢
DEBT / EBITDA (TTM)
—
+91%0.6x2.8x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 96.49%INSIDERS 0.19%OTHER / RETAIL 3.32%1,480 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 10.81% | 16.0M | $3.32B | +7.8% |
| Primecap Management Company | 9.99% | 14.8M | $3.07B | +0.0% |
| FMR, LLC | 8.67% | 12.8M | $2.66B | +35.9% |
| Vanguard Capital Management LLC | 6.45% | 9.5M | $1.98B | NEW |
| State Street Corporation | 4.85% | 7.2M | $1.49B | +0.1% |
| Vanguard Portfolio Management LLC | 4.42% | 6.5M | $1.36B | NEW |
| Geode Capital Management, LLC | 2.94% | 4.3M | $903.0M | +3.4% |
| Wellington Management Group, LLP | 2.00% | 3.0M | $615.8M | -16.6% |
| Morgan Stanley | 1.47% | 2.2M | $451.4M | -6.6% |
| JPMORGAN CHASE & CO | 1.36% | 2.0M | $419.2M | +8.6% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.